X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
natalizumab (522) 522
humans (413) 413
index medicus (324) 324
multiple sclerosis (308) 308
pharmacology & pharmacy (232) 232
multiple sclerosis - drug therapy (173) 173
progressive multifocal leukoencephalopathy (164) 164
female (147) 147
male (135) 135
animals (127) 127
adult (125) 125
antibodies, monoclonal, humanized (118) 118
antibodies, monoclonal - therapeutic use (115) 115
clinical neurology (113) 113
middle aged (99) 99
drug therapy (93) 93
placebo-controlled trial (91) 91
antibodies, monoclonal, humanized - therapeutic use (89) 89
neurosciences (87) 87
glatiramer acetate (80) 80
neurology (79) 79
therapy (75) 75
treatment outcome (73) 73
double-blind (70) 70
antibodies, monoclonal - pharmacology (69) 69
care and treatment (69) 69
multiple sclerosis, relapsing-remitting - drug therapy (68) 68
crohn's disease (66) 66
multiple-sclerosis (65) 65
medicine & public health (60) 60
immunology (59) 59
multiple sclerosis - immunology (59) 59
fingolimod (58) 58
disease (56) 56
immunosuppressive agents - therapeutic use (56) 56
monoclonal antibodies (55) 55
alemtuzumab (52) 52
risk factors (52) 52
antibodies, monoclonal - adverse effects (51) 51
research (51) 51
antibodies, monoclonal, humanized - pharmacology (48) 48
interferon (48) 48
patients (48) 48
immunologic factors - therapeutic use (45) 45
crohn disease - drug therapy (44) 44
infliximab (44) 44
natalizumab, adverse reactions (42) 42
experimental autoimmune encephalomyelitis (40) 40
health aspects (40) 40
natalizumab - therapeutic use (40) 40
rituximab (40) 40
safety (40) 40
inflammation (39) 39
jc virus (39) 39
mice (39) 39
young adult (39) 39
clinical trials (37) 37
leukoencephalopathy, progressive multifocal - chemically induced (37) 37
maintenance therapy (37) 37
drugs (36) 36
efficacy (36) 36
immunosuppressive agents - adverse effects (36) 36
medicine (36) 36
risk (36) 36
ulcerative colitis (36) 36
integrin (35) 35
integrins (35) 35
pharmacology/toxicology (35) 35
adalimumab (34) 34
analysis (34) 34
inflammatory bowel disease (34) 34
inflammatory-bowel-disease (34) 34
interferon beta-1a (33) 33
progressive-multifocal-leukoencephalopathy, drug-i (33) 33
antibodies (32) 32
antibodies, monoclonal, humanized - adverse effects (32) 32
clinical trials as topic (32) 32
integrin alpha4 - immunology (32) 32
medicine, research & experimental (32) 32
review (32) 32
disability (31) 31
lymphocytes (31) 31
magnetic resonance imaging (31) 31
natalizumab, adverse reactions - serious (31) 31
vedolizumab (31) 31
controlled trial (30) 30
immunologic factors - pharmacology (30) 30
multiple sclerosis - therapy (30) 30
natalizumab - pharmacology (30) 30
natalizumab, therapeutic use (30) 30
studies (30) 30
crohns-disease (29) 29
expression (29) 29
oral fingolimod (29) 29
disease-activity (28) 28
integrin alpha4beta1 - antagonists & inhibitors (28) 28
psychiatry (28) 28
abridged index medicus (27) 27
disease progression (27) 27
interferon-beta (27) 27
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Neurology, ISSN 0340-5354, 10/2008, Volume 255, Issue 10, pp. 1449 - 1463
This review updates and extends earlier Consensus Reports related to current basic and escalating immunomodulatory treatments in multiple sclerosis (MS). The... 
Multiple Sclerosis | Neurology | randomized trials | Neurosciences | Medicine & Public Health | glatirameracetate | treatment escalation | interferon β | immunotherapy | Neuroradiology | monoclonal antibodies | Treatment escalation | Glatirameracetate | Interferon β | Multiple sclerosis | Randomized trials | Immunotherapy | Monoclonal antibodies | interferon beta | EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS | NEUTRALIZING ANTIBODIES | CLINICAL NEUROLOGY | 1ST DEMYELINATING EVENT | GLATIRAMER ACETATE COPAXONE(R) | INTERFERON-BETA THERAPY | DOUBLE-BLIND | INTRAVENOUS IMMUNOGLOBULIN TREATMENT | PLACEBO-CONTROLLED TRIAL | CLINICALLY ISOLATED SYNDROMES | MITOXANTRONE-INDUCED CARDIOTOXICITY | Azathioprine - therapeutic use | Multiple Sclerosis - diagnosis | Natalizumab | Humans | Antibodies, Monoclonal - adverse effects | Health Planning Guidelines | Glatiramer Acetate | Antibodies, Monoclonal - therapeutic use | Interferon-beta - therapeutic use | Antibodies, Monoclonal, Humanized | Societies - standards | Mitoxantrone - therapeutic use | Antibodies, Monoclonal - pharmacology | Europe | Immunologic Factors - administration & dosage | Azathioprine - pharmacology | Immunoglobulins, Intravenous - pharmacology | Multiple Sclerosis - therapy | Peptides - pharmacology | Plasmapheresis | Randomized Controlled Trials as Topic | Magnetic Resonance Imaging | Immunoglobulins, Intravenous - therapeutic use | Interferon-beta - pharmacology | Mitoxantrone - pharmacology | Peptides - therapeutic use | Immunologic Factors - therapeutic use | Care and treatment | Health aspects | Patient outcomes
Journal Article
Annals of Neurology, ISSN 0364-5134, 03/2015, Volume 77, Issue 3, pp. 425 - 435
Journal Article
Acta medica Croatica : casopis Hravatske akademije medicinskih znanosti, ISSN 1330-0164, 04/2013, Volume 67, Issue 2, p. 125
Journal Article
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, ISSN 0306-5251, 12/2014, Volume 78, Issue 6, pp. 1315 - 1333
AimsAMG 181 pharmacokinetics/pharmacodynamics (PK/PD), safety, tolerability and effects after single subcutaneous (s.c.) or intravenous (i.v.) administration... 
CROHNS-DISEASE | NATALIZUMAB | T cell trafficking | INDUCTION | CERTOLIZUMAB PEGOL | MAINTENANCE THERAPY | PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY | MULTIPLE-SCLEROSIS | BETA 7 | AMG 181 | PHARMACOLOGY & PHARMACY | ulcerative colitis | ACTIVE ULCERATIVE-COLITIS | integrin | T-CELLS
Journal Article
BRITISH JOURNAL OF PHARMACOLOGY, ISSN 0007-1188, 05/2013, Volume 169, Issue 1, pp. 51 - 68
Background and Purpose AMG 181 is a human anti-47 antibody currently in phase 1 and 2 trials in subjects with inflammatory bowel diseases. AMG 181 specifically... 
inflammatory bowel diseases | INTEGRIN | ULCERATIVE-COLITIS | BETA-7 | Crohn's disease | MONOCLONAL-ANTIBODY | NATALIZUMAB | MUCOSAL | anti-alphabeta | T cells | ACTIVE CROHNS-DISEASE | VEDOLIZUMAB | ADHESION | alphabeta integrin | AFFINITY | AMG 181 | gut-homing | cell trafficking | PHARMACOLOGY & PHARMACY | ulcerative colitis | human antibody
Journal Article
Drugs, ISSN 0012-6667, 10/2017, Volume 77, Issue 16, pp. 1755 - 1768
Since the approval of fingolimod, several selective sphingosine-1-phosphate receptor modulators have entered clinical development for multiple sclerosis.... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | LONG-TERM | BAF312 SIPONIMOD | TUMEFACTIVE MS | ORAL FINGOLIMOD FTY720 | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | OPEN-LABEL | TOXICOLOGY | PLACEBO-CONTROLLED TRIAL | DISEASE-MODIFYING THERAPIES | SAFETY PROFILE | CLINICAL-PRACTICE | Fingolimod Hydrochloride - pharmacology | Multiple Sclerosis - diagnosis | Risk Assessment | Humans | Natalizumab - adverse effects | Natalizumab - chemistry | Natalizumab - pharmacology | Fingolimod Hydrochloride - chemistry | Natalizumab - administration & dosage | Multiple Sclerosis - immunology | Immunosuppressive Agents - adverse effects | Receptors, Lysosphingolipid - metabolism | Fingolimod Hydrochloride - adverse effects | Immunosuppressive Agents - pharmacology | Immunosuppressive Agents - administration & dosage | Immunosuppressive Agents - chemistry | Fingolimod Hydrochloride - administration & dosage | Multiple Sclerosis - drug therapy | Multiple sclerosis | Care and treatment | Usage | Dosage and administration | Fingolimod | Drug therapy | Short term | Phosphates | Washouts | Nervous system | Malignancy | Modulators | Sphingosine 1-phosphate | Cell adhesion & migration | Lymphocytes | Phosphate | Risk assessment | Safety | Patient satisfaction | Heart diseases | Drug dosages | Edema | Lymphatic system | Effectiveness | Immunomodulation | Switching | Studies | Heart rate | Side effects | Titration | Review
Journal Article
Multiple Sclerosis Journal, ISSN 1352-4585, 10/2016, Volume 22, Issue 12, pp. 1587 - 1595
Journal Article
Journal Article
Journal Article